GB2113546A - Treatment of migraine - Google Patents

Treatment of migraine Download PDF

Info

Publication number
GB2113546A
GB2113546A GB08201911A GB8201911A GB2113546A GB 2113546 A GB2113546 A GB 2113546A GB 08201911 A GB08201911 A GB 08201911A GB 8201911 A GB8201911 A GB 8201911A GB 2113546 A GB2113546 A GB 2113546A
Authority
GB
United Kingdom
Prior art keywords
levo
migraine
paracetamol
hydroxytryptophan
tryptophan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB08201911A
Inventor
Selwyn Leon Dexter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAYRON INTERNATIONAL Inc
Original Assignee
MAYRON INTERNATIONAL Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAYRON INTERNATIONAL Inc filed Critical MAYRON INTERNATIONAL Inc
Priority to GB08201911A priority Critical patent/GB2113546A/en
Publication of GB2113546A publication Critical patent/GB2113546A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical compositions for treating migraine comprise a mixture of 1-tryptophan or 5-hydroxytryptophan and a peripherally acting analgesic e.g. paracetamol.

Description

SPECIFICATION Pharmaceutical composition This invention relates to pharmaceutical compositions for the treatment of migraine.
Migraine, in both its common and classical forms, and its associated disorders, is estimated to affect from 8-12% of the population. Numerous compounds have been proposed for the treatment of migraine both on a preventative basis and on an acute basis, but the need still exists for an effective anti-migraine treatment.
In accordance with the present invention, it has been found that levo-tryptophan, or levo - 5 hydroxytryptophan, which is known metabolite of levo-tryptophan, is a useful adjunct two peripherally acting analgesics such as paracetamol, in the alleviation of the acute symptoms of migraine. The use of levo-tryptophan in migranetreatment has been discussed in some detail in 'headache', Volume 18, No.3, (July 1978) page 161, but combination thereby in conjunction with peripherally acting analgesics is not discussed.
In one aspect, the present invention provides a pharmaceutical composition for the treatment of migraine comprising in admixture levo-tryptophan, or levo - 5 - hydroxytryptophan, and a peripherally acting analgesic, preferably paracetamol.
In another aspect, the present invention provides a method of alleviating the acute symptoms of mig rainewhich comprises administering both levotryptophan, or levo - 5 - hydroxytryptophan, and a peripherally, acting analgesic, preferably paracetamol.
The pharmaceutical compositions of the present invention are preferably in tablet form for oral administration comprising levo-tryptophan, or levo 5 - hydroxytryptophan, and the peripherally acting analgesic, e.g. paracetamol, in admixture in a tabletting carrier.
In the combination therapy ofthe present invention the effective dose range of levo-tryptophan, or levo - 5 - hydroxytryptophan is from 5-3000 mgs, four to six hourly, preferably 500-1500 mgs, and from 50-1500 mgs paracetamol. Tablets for oral administration will be formulated accordingly, conveniently each as a single dosage unit containing from 5-3000 mgs, preferably 5-1500 mgs, levo-tryptophan, or levo - 5 hydroxytryptophan, and from 50-1500 mgs paracetamol.
Otherformulations, e.g. liquid suspensions, for oral orfor rectal administration will be obvious to those skilled in the art.
Instead of paracetamol, other p-aminophenols having peripheral analgesic activity may be used.
The pharmaceutical compositions of the invention may also include other active ingredients, for example, caffeine, and as migraine is often associated with gastric stress drug, such as metaclopramide, which restores gastric mobility, increase drug absorption and reduce nausea, can be added.
1. A pharmaceutical composiiton fo r the treat- ment of migraine comprising in admixture levotryptophan, or levo - 5 - hydroxytryptophan and a peripherally acting analgesic.
2. A composition according to claim 3, wherein the analgesic is paracetamol.
3. A composition according to any one of the preceding claims in tablet form.
**WARNING** end of DESC field may overlap start of CLMS **.

Claims (3)

**WARNING** start of CLMS field may overlap end of DESC **. SPECIFICATION Pharmaceutical composition This invention relates to pharmaceutical compositions for the treatment of migraine. Migraine, in both its common and classical forms, and its associated disorders, is estimated to affect from 8-12% of the population. Numerous compounds have been proposed for the treatment of migraine both on a preventative basis and on an acute basis, but the need still exists for an effective anti-migraine treatment. In accordance with the present invention, it has been found that levo-tryptophan, or levo - 5 hydroxytryptophan, which is known metabolite of levo-tryptophan, is a useful adjunct two peripherally acting analgesics such as paracetamol, in the alleviation of the acute symptoms of migraine. The use of levo-tryptophan in migranetreatment has been discussed in some detail in 'headache', Volume 18, No.3, (July 1978) page 161, but combination thereby in conjunction with peripherally acting analgesics is not discussed. In one aspect, the present invention provides a pharmaceutical composition for the treatment of migraine comprising in admixture levo-tryptophan, or levo - 5 - hydroxytryptophan, and a peripherally acting analgesic, preferably paracetamol. In another aspect, the present invention provides a method of alleviating the acute symptoms of mig rainewhich comprises administering both levotryptophan, or levo - 5 - hydroxytryptophan, and a peripherally, acting analgesic, preferably paracetamol. The pharmaceutical compositions of the present invention are preferably in tablet form for oral administration comprising levo-tryptophan, or levo 5 - hydroxytryptophan, and the peripherally acting analgesic, e.g. paracetamol, in admixture in a tabletting carrier. In the combination therapy ofthe present invention the effective dose range of levo-tryptophan, or levo - 5 - hydroxytryptophan is from 5-3000 mgs, four to six hourly, preferably 500-1500 mgs, and from 50-1500 mgs paracetamol. Tablets for oral administration will be formulated accordingly, conveniently each as a single dosage unit containing from 5-3000 mgs, preferably 5-1500 mgs, levo-tryptophan, or levo - 5 hydroxytryptophan, and from 50-1500 mgs paracetamol. Otherformulations, e.g. liquid suspensions, for oral orfor rectal administration will be obvious to those skilled in the art. Instead of paracetamol, other p-aminophenols having peripheral analgesic activity may be used. The pharmaceutical compositions of the invention may also include other active ingredients, for example, caffeine, and as migraine is often associated with gastric stress drug, such as metaclopramide, which restores gastric mobility, increase drug absorption and reduce nausea, can be added. CLAIMS
1. A pharmaceutical composiiton fo r the treat- ment of migraine comprising in admixture levotryptophan, or levo - 5 - hydroxytryptophan and a peripherally acting analgesic.
2. A composition according to claim 3, wherein the analgesic is paracetamol.
3. A composition according to any one of the preceding claims in tablet form.
GB08201911A 1982-01-22 1982-01-22 Treatment of migraine Withdrawn GB2113546A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB08201911A GB2113546A (en) 1982-01-22 1982-01-22 Treatment of migraine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08201911A GB2113546A (en) 1982-01-22 1982-01-22 Treatment of migraine

Publications (1)

Publication Number Publication Date
GB2113546A true GB2113546A (en) 1983-08-10

Family

ID=10527833

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08201911A Withdrawn GB2113546A (en) 1982-01-22 1982-01-22 Treatment of migraine

Country Status (1)

Country Link
GB (1) GB2113546A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004170A1 (en) * 1986-12-13 1988-06-16 Joachim Kamprad Pain-killer
WO1999023881A1 (en) * 1997-11-12 1999-05-20 Allocca Technical, Inc. Composition and method for preventing or alleviating migraine headaches
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO2018071656A1 (en) * 2016-10-14 2018-04-19 Knowles Enterprises Inc. Formulations for treatment of migraines

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004170A1 (en) * 1986-12-13 1988-06-16 Joachim Kamprad Pain-killer
US5216019A (en) * 1986-12-13 1993-06-01 Joachim Kamprad Pain killer
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO1999023881A1 (en) * 1997-11-12 1999-05-20 Allocca Technical, Inc. Composition and method for preventing or alleviating migraine headaches
US5939076A (en) * 1997-11-12 1999-08-17 Allocca Techical, Inc. Composition and method for treating or alleviating migraine headaches
GB2348133A (en) * 1997-11-12 2000-09-27 Allocca Technical Inc Composition and method for preventing or alleviating migraine headaches
WO2018071656A1 (en) * 2016-10-14 2018-04-19 Knowles Enterprises Inc. Formulations for treatment of migraines

Similar Documents

Publication Publication Date Title
NZ288298A (en) Hydroxamic acid and carboxylic acid derivatives; medicaments containing such derivatives that are metalloproteinase inhibitors
RU94040864A (en) Fused indole derivatives, their synthesis, pharmaceutical composition
RU94041223A (en) Agent for motoneuron disease treatment
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
ATE30575T1 (en) STABILIZED ACTIVATED OXYGEN AND PHARMACEUTICALS CONTAINING SUCH STABILIZED ACTIVATED OXYGEN.
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
ATE293451T1 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
MX173567B (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION
RU94045278A (en) Use of 2-phenyl-3-aroylbenzothiophenes for vasomotor symptom and associated psychological disorder inhibition associated with postclimacteric syndrome
RU95101385A (en) Products containing g-csf and tnf-binding protein
JPS5234935A (en) Medicinal composition
RU94044438A (en) Use of 2-phenyl-3-aroylbenzthiophenes for contraception suppression in women
RU94045866A (en) Use of bis-phenylalkylpiperazines for treatment of disorders caused by substance abuse, method of treatment
GB2113546A (en) Treatment of migraine
US3008874A (en) Pharmaceutical compositions
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
IL70407A (en) Synergistic analgesic pharmaceutical compositions in unit dosage form,comprising an analgesic agent and hydroxyzine
Giunchi et al. Trimethoprim-sulfamethoxazole combination in the treatment of acute human brucellosis.
GB2113545A (en) Treatment of migraine
RU94032792A (en) Application of 5htia-antagonists for tobacco use stopping
GB2113544A (en) Treatment of migraine
US4885288A (en) Pharmaceutical compositions containing lysine acetylsalicylate
MXPA00011557A (en) Method for treating migraine symptoms with ibuprofen and salts thereof.
EP0785779A1 (en) Low dosage ketoprofen

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)